Condition: Migraine Disorders · Chronic Migraine · Episodic Migraine · Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation
Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group. They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment. The clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients
This description comes directly from the study's public registry record.
Roberto De Icco · 00390382380425 · roberto.deicco@mondino.it
Cinzia Fattore · 00390382380385 · cinzia.fattore@mondino.it
Always discuss trial participation with your own doctor first.
| Headache Science & Neurorehabilitation Unit | Pavia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06562400